Disease · MONDO_0003778
Comparisons in its trials27
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 27
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| IV Administration of IGIV, 10% vs SC Administration of IGIV, 10%, With rHuPH20 (With Ramp-up): serious adverse events | 3 of 87 | 12 of 83 | 170 | NCT00814320 | Trial comparisons |
| IGSC, 10% - rHuPH20 vs Safety Follow-up - IGSC, 10% or IGIV, 10% Only: serious adverse events | 9 of 63 | 3 of 51 | 114 | NCT01175213 | Trial comparisons |
| Epoch 1 vs Epoch 2: Number of Participants With All Temporally Associated TEAEs Excluding Infections | 27 of 44 | 35 of 43 | 87 | NCT03277313 | Trial comparisons |
| Epoch 1 vs Epoch 2: Number of Participants With All Related (Causally) and/or Temporally Associated TEAEs Excluding Infections | 27 of 44 | 35 of 43 | 87 | NCT03277313 | Trial comparisons |
| Epoch 1 vs Epoch 2: deaths from any cause | 0 of 44 | 0 of 43 | 87 | NCT03277313 | Trial comparisons |
| Epoch 1 vs Epoch 2: serious adverse events | 1 of 44 | 3 of 43 | 87 | NCT03277313 | Trial comparisons |
| Gammaplex 5% - All Subjects vs Gammaplex 10% - All Subjects: deaths from any cause | 0 of 33 | 0 of 47 | 80 | NCT01963143 | Trial comparisons |
| Gammaplex 5% - All Subjects vs Gammaplex 10% - All Subjects: serious adverse events | 2 of 33 | 1 of 47 | 80 | NCT01963143 | Trial comparisons |
| Epochs 1+2 (SC Treatment w/ IGI,10% and rHuPH20, n=37) vs Safety Follow-up (n=26): serious adverse events | 0 of 37 | 1 of 26 | 63 | NCT01485796 | Trial comparisons |
| HyQvia New Starters vs HyQvia Pre-treated: Safety: Number of Participants With Local TEAEs (Excluding Infections) | 11 of 23 | 3 of 19 | 42 | NCT03116347 | Trial comparisons |
| HyQvia New Starters vs HyQvia Pre-treated: Safety: Number of Participants With Any Related Serious TEAEs Per Infusion (Excluding Infections) | 0 of 23 | 0 of 19 | 42 | NCT03116347 | Trial comparisons |
| HyQvia New Starters vs HyQvia Pre-treated: Safety: Number of Participants With Any Severe Related Treatment-emergent Adverse Events (TEAEs) Per Infusion (Excluding Infections) | 1 of 23 | 0 of 19 | 42 | NCT03116347 | Trial comparisons |
| HyQvia New Starters vs HyQvia Pre-treated: Safety: Number of Participants With Any Adverse Reactions (Excluding Infections) | 12 of 23 | 3 of 19 | 42 | NCT03116347 | Trial comparisons |
| HyQvia New Starters vs HyQvia Pre-treated: Safety: Number of Participants With Any TEAEs (Excluding Infections) | 18 of 23 | 11 of 19 | 42 | NCT03116347 | Trial comparisons |
| HyQvia New Starters vs HyQvia Pre-treated: Safety: Number of Participants With Any Related (Causally) and/or Temporally Associated TEAEs (Excluding Infections) | 13 of 23 | 6 of 19 | 42 | NCT03116347 | Trial comparisons |
| HyQvia New Starters vs HyQvia Pre-treated: Safety: Number of Participants With Local Adverse Reaction (Excluding Infections) | 11 of 23 | 3 of 19 | 42 | NCT03116347 | Trial comparisons |
| HyQvia New Starters vs HyQvia Pre-treated: Safety: Number of Participants With Any Serious TEAEs (Excluding Infections) | 0 of 23 | 3 of 19 | 42 | NCT03116347 | Trial comparisons |
| HyQvia New Starters vs HyQvia Pre-treated: Safety: Number of Participants With Any Temporally Associated TEAEs (Excluding Infections) | 13 of 23 | 6 of 19 | 42 | NCT03116347 | Trial comparisons |
| HyQvia New Starters vs HyQvia Pre-treated: Safety: Number of Participants With Systemic TEAEs (Excluding Infections) | 15 of 23 | 10 of 19 | 42 | NCT03116347 | Trial comparisons |
| HyQvia New Starters vs HyQvia Pre-treated: deaths from any cause | 0 of 23 | 0 of 19 | 42 | NCT03116347 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0003778/comparisons